Goldman Sachs Turns Bearish on MoonLake
Goldman Sachs downgraded MoonLake Immunotherapeutics to Sell, citing high approval risks despite progress in Phase 3 trials.
Already have an account? Sign in.
Goldman Sachs downgraded MoonLake Immunotherapeutics to Sell, citing high approval risks despite progress in Phase 3 trials.
SpaceX’s Starship upper stage returned from a 22-hour orbital mission and was caught by the launch tower for the first time, marking a key reusability milestone.
The Financial Times reports Amazon is the hyperscaler behind Fermi America’s new 600 MW power deals following the breakdown of 2025 talks.
Meta’s internal prediction market app Takes lets employees bet with credibility points instead of cash. Launch plans remain unclear.
Be the first to know when deals break, stocks move, or biotech headlines hit.